Topoisomerase II alpha, rather than II beta, is a promising target in development of anti-cancer drugs

被引:53
作者
Chen, Wang [1 ]
Qiu, Jin [1 ,2 ]
Shen, Yuemao [1 ]
机构
[1] Shandong Univ, Sch Pharmaceut Sci, 44 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Sch Pharmaceut Sci, Jinan, Shandong, Peoples R China
关键词
Topoisomerase II alpha; topoisomerase II beta; therapeutic target; inhibitors; cancer therapy;
D O I
10.5582/ddt.2012.v6.5.230
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
DNA topoisomerase II (TOP2) is a wellknown anticancer target. Its inhibitors are among the most effective anticancer drugs currently in clinical use. TOP2-targeting agents fall into two major classes of "Topo poisons" and "Topo inhibitors" based on their mechanisms of action. Mammalian cells possess two genetically distinct TOP2 isoforms, TOP2 alpha and TOP2 beta, that are differentially regulated and play different roles in living cells. Compared to TOP2 beta, TOP2 alpha may be an efficacious and safe chemotherapeutic target for cancer treatment. This review discusses the advantage of targeting TOP2 alpha over TOP2 beta and action of various agents on TOP2 alpha.
引用
收藏
页码:230 / 237
页数:8
相关论文
共 59 条
[1]
Catalytic inhibitors of DNA topoisomerase II [J].
Andoh, T ;
Ishida, R .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :155-171
[2]
NOVEL HELA TOPOISOMERASE-II IS THE II-BETA ISOFORM - COMPLETE CODING SEQUENCE AND HOMOLOGY WITH OTHER TYPE-II TOPOISOMERASES [J].
AUSTIN, CA ;
SNG, JH ;
PATEL, S ;
FISHER, LM .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1172 (03) :283-291
[3]
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies [J].
Azarova, Anna M. ;
Lyu, Yi Lisa ;
Lin, Chao-Po ;
Tsai, Yuan-Chin ;
Lau, Johnson Yiu-Nam ;
Wang, James C. ;
Liu, Leroy F. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (26) :11014-11019
[4]
Bender Ryan P., 2008, P57, DOI 10.1007/978-1-59745-274-8_3
[5]
Inhibition of topoisomerase IIα: Novel function of wedelolactone [J].
Benes, Petr ;
Knopfova, Lucia ;
Trcka, Filip ;
Nemajerova, Alice ;
Pinheiro, Diana ;
Soucek, Karel ;
Fojta, Miroslav ;
Smarda, Jan .
CANCER LETTERS, 2011, 303 (01) :29-38
[6]
Structure of the topoisomerase VI-B subunit: implications for type II topoisomerase mechanism and evolution [J].
Corbett, KD ;
Berger, JM .
EMBO JOURNAL, 2003, 22 (01) :151-163
[7]
Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review [J].
De Beer, EL ;
Bottone, AE ;
Voest, EE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 415 (01) :1-11
[8]
Structural basis for gate-DNA recognition and bending by type IIA topoisomerases [J].
Dong, Ken C. ;
Berger, James M. .
NATURE, 2007, 450 (7173) :1201-U4
[9]
Unprecedented Citrinin Trimer Tricitinol B Functions as a Novel Topoisomerase IIα Inhibitor [J].
Du, Lin ;
Liu, Hong-Chun ;
Fu, Wei ;
Li, De-Hai ;
Pan, Qiu-Ming ;
Zhu, Tian-Jiao ;
Geng, Mei-Yu ;
Gu, Qan-Qun .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (16) :5796-5810
[10]
Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice [J].
Fortune, JM ;
Osheroff, N .
PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 64, 2000, 64 :221-253